Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India

BACKGROUND: Mycobacterium tuberculosis (Mtb) strains resistant to isoniazid and rifampin (multidrug-resistant tuberculosis [MDR-TB]) are increasingly reported worldwide, requiring renewed focus on the nuances of drug resistance. Patients with low-level moxifloxacin resistance may benefit from higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Tornheim, Jeffrey A, Udwadia, Zarir F, Arora, Prerna R, Gajjar, Ishita, Sharma, Samridhi, Karane, Megha, Sawant, Namrata, Kharat, Nisha, Blum, Alexander J, Shivakumar, Shri Vijay Bala Yogendra, Gupte, Akshay N, Gupte, Nikhil, Mullerpattan, Jai B, Pinto, Lancelot M, Ashavaid, Tester F, Gupta, Amita, Rodrigues, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794589/
https://www.ncbi.nlm.nih.gov/pubmed/35097152
http://dx.doi.org/10.1093/ofid/ofab615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794589/
https://www.ncbi.nlm.nih.gov/pubmed/35097152
http://dx.doi.org/10.1093/ofid/ofab615

Ejemplares similares